HOSPITAL UNIVERSITARIO RUBER
Departamento
Universitat Autònoma de Barcelona
Barcelona, EspañaPublicaciones en colaboración con investigadores/as de Universitat Autònoma de Barcelona (49)
2023
-
Analysis of tumor infiltrating CD4+ and CD8+ CDR3 sequences reveals shared features putatively associated to the anti-tumor immune response
Frontiers in Immunology, Vol. 14
-
Cyclin-Dependent Kinase 4/6 Inhibitors and Dermatologic Adverse Events: Results from the EADV Task Force “Dermatology for Cancer Patients” International Study
Cancers, Vol. 15, Núm. 14
-
Evaluation of triple negative breast cancer with heterogeneous immune infiltration
Frontiers in Immunology, Vol. 14
2022
-
Clinical associations and classification of immune checkpoint inhibitor-induced cutaneous toxicities: a multicentre study from the European Academy of Dermatology and Venereology Task Force of Dermatology for Cancer Patients*
British Journal of Dermatology, Vol. 187, Núm. 6, pp. 962-969
-
Evaluation of the TCR Repertoire as a Predictive and Prognostic Biomarker in Cancer: Diversity or Clonality?
Cancers, Vol. 14, Núm. 7
-
Identification of a Molecularly-Defined Subset of Breast and Ovarian Cancer Models that Respond to WEE1 or ATR Inhibition, Overcoming PARP Inhibitor Resistance
Clinical Cancer Research, Vol. 28, Núm. 20, pp. 4536-4550
-
Therapy-Induced Senescence Enhances the Efficacy of HER2-Targeted Antibody-Drug Conjugates in Breast Cancer
Cancer research, Vol. 82, Núm. 24, pp. 4670-4679
2021
-
Environmental exposure during pregnancy: Influence on prenatal development and early life: A comprehensive review
Fetal Diagnosis and Therapy, Vol. 48, Núm. 4, pp. 245-257
-
Epstein–Barr Virus+ B Cells in Breast Cancer Immune Response: A Case Report
Frontiers in Immunology, Vol. 12
-
Immune analysis of lymph nodes in relation to the presence or absence of tumor infiltrating lymphocytes in triple-negative breast cancer
European Journal of Cancer, Vol. 148, pp. 134-145
-
PI3K activation promotes resistance to eribulin in HER2-negative breast cancer
British Journal of Cancer, Vol. 124, Núm. 9, pp. 1581-1591
2020
-
Enhancing global access to cancer medicines
CA Cancer Journal for Clinicians, Vol. 70, Núm. 2, pp. 105-124
-
Five microRNAs in Serum Are Able to Differentiate Breast Cancer Patients From Healthy Individuals
Frontiers in Oncology, Vol. 10
-
Inclusion of non-inferiority analysis in superiority-based clinical trials with single-arm, two-stage Simon's design
Contemporary Clinical Trials Communications, Vol. 20
-
The evolving microbiome from pregnancy to early infancy: A comprehensive review
Nutrients, Vol. 12, Núm. 1
-
The second generation antibody-drug conjugate syd985 overcomes resistances to T-DM1
Cancers, Vol. 12, Núm. 3
2019
-
The Genomic and Immune Landscapes of Lethal Metastatic Breast Cancer
Cell Reports, Vol. 27, Núm. 9, pp. 2690-2708.e10
2018
-
MSK1 regulates luminal cell differentiation and metastatic dormancy in ER + breast cancer
Nature Cell Biology, Vol. 20, Núm. 2, pp. 211-221
-
A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation
EMBO Molecular Medicine, Vol. 10, Núm. 12
-
Erratum to: MSK1 regulates luminal cell differentiation and metastatic dormancy in ER+ breast cancer (Nature Cell Biology, (2018), 20, 2, (211-221), 10.1038/s41556-017-0021-z)
Nature Cell Biology